Biopharm Skyrockets 150% Today

September 16, 2024 | [Read Online]( Biopharm Skyrockets 150% Today [fb]( [fb]( [fb]( [fb](mailto:?subject=Post%20from%20Elite%20Trade%20Club&body=Biopharm%20Skyrockets%20150%25%20Today%3A%20%0A%0Ahttps%3A%2F%2Felitetrade.club%2Fp%2Fbiopharm-skyrockets-150-today) Good Afternoon! Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today. Markets 📈 U.S. indexes start off the week as a bit of a mixed bag. The Dow Jones ended the day in the best shape, climbing half a point from Friday’s total. - DJIA [+0.55%] - S&P 500 [+0.13%] - Nasdaq [-0.52%] - Russell 2K [+0.31%] Public Safety [Could This Be the AI Stock to Make You Rich?]( This innovative AI stock delivered a 128% revenue surge in 2023, yet it remains undervalued with a market cap under $35 million. Their cutting-edge technology—[Autonomous Security Robots](and gunshot detection systems—is already transforming public safety and generating consistent, recurring revenue. With over 30 new contracts, including a major deal with the U.S. Federal Government, this company is primed for significant growth in the booming AI security market. [This is your chance to get in early and ride the wave of what could be the next major AI stock. Don’t miss out—act now and start building real wealth today.]( Market-Moving News 📈 Tesla Faces Roadblocks as Supercharger Expansion Slows Tesla's Supercharger network, once known for its fast expansion, now faces significant setbacks. Following layoffs in April that affected the team managing new charging station installations, the company noted a noticeable lag in its production. Although Tesla has begun rehiring staff and restructuring the team, the pace of adding new Superchargers between May and August has fallen behind last year’s figures. Despite receiving government funds to enhance its charging infrastructure, Tesla is under increasing pressure to keep up with growing demand. The company now needs to extend its network to accommodate non-Tesla vehicles, a result of recent collaborations with other automakers. This shift has sparked concerns about overcrowding at existing charging stations, as Tesla owners worry about longer wait times. While construction on new stations is still ongoing, several challenges remain. Delays in rolling out adapters for non-Tesla vehicles and technical difficulties have slowed progress. With a smaller workforce and new leadership guiding the initiative, Tesla is cautiously navigating this critical phase. The company’s dominance in the EV charging sector could face challenges as it works to maintain its competitive edge. As more car manufacturers join the Supercharger network, ensuring its efficiency and smooth operation becomes even more vital for Tesla’s continued success. Pfizer's Breakthrough Drug May Revolutionize Cancer Treatment Pfizer's promising new drug for cancer cachexia, a severe condition that causes significant weight loss and reduced appetite in cancer patients, has shown encouraging results in a mid-stage trial. This condition, which affects millions globally, leads to muscle and fat loss, resulting in weakness and a diminished quality of life. Pfizer's investigational drug, ponsegromab, a monoclonal antibody, has demonstrated potential in improving body weight, muscle mass, and overall well-being in patients suffering from this debilitating condition. The trial involved patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer who exhibited high levels of a protein known as GDF-15, which influences appetite. After a 12-week period, those receiving the highest dose of ponsegromab experienced a notable increase in body weight compared to those on a placebo. Lower doses of the drug also led to weight gain, although to a lesser extent. These results suggest that ponsegromab could be the first approved treatment specifically targeting cancer cachexia in the U.S. The data, presented at the European Society for Medical Oncology 2024 Congress and published in The New England Journal of Medicine, indicates that ponsegromab effectively lowers GDF-15 levels, which may enhance appetite and aid in weight maintenance. Pfizer is planning further studies and discussions with regulators to advance the drug's development, with hopes of initiating late-stage trials by 2025. The company is also exploring ponsegromab's potential in treating cachexia associated with heart failure. LG's Smart Home Overhaul: ThinQ ON Hub Aims to Revolutionize Connectivity LG is making a bold move into the smart home sector with several new developments. The company is launching its latest innovation, the ThinQ ON hub, which marks a significant upgrade from its previous home automation efforts. This new hub supports multiple connectivity protocols including Matter, Thread, Zigbee, and Wi-Fi, and functions as both a smart speaker and a hub with a built-in AI assistant. The ThinQ ON hub is designed to work seamlessly with a wide range of smart home devices, expanding LG’s ThinQ platform beyond just managing LG appliances. The AI assistant, powered by LG’s “Affectionate Intelligence,” aims to enhance home automation by learning from user preferences and adjusting home settings like temperature and fan speed autonomously. In addition to integrating various smart devices into its ecosystem, LG plans to open its platform to other smart home systems. This move allows LG appliances to connect with different ecosystems, offering users greater flexibility in their smart home setups. The company has also acquired Athom, incorporating its Homey OS into the ThinQ ON hub, which will bring compatibility with a broad array of devices from other manufacturers. LG’s approach is set to position it as a strong competitor in the smart home arena, potentially rivaling established platforms from Apple, Amazon, and Google. The ThinQ ON hub and expanded platform are expected to roll out in the US and Europe next year, promising to offer a more integrated and versatile smart home experience. [Discover Explosive Trading with the "APEX" System]( Traders have been spotting double- and triple-digit moves at every single market open, within hours or just minutes. Recent bangers include 150% on ET, 220% on BHC, 190% on CRK, and many more! These "APEX" trades happen practically every trading day, thanks to a system built by 4 pro traders who share their top trade ideas daily at zero cost. So, are you ready to get in on these explosive trade ideas? [Click here to unlock instant, no-cost access to BIG day-trade alerts.]( Top Winners and Losers 🔥 NuCana plc ADR [NCNA] $6.37 (+150.79%) NuCana shared promising data from its resistant melanoma study, prompting investor excitement. REE Automotive [REE] $4.34 (+46.37%) REE Automative made waves after unveiling a global manufacturing agreement with automotive supplier Motherson Group Greenlane Holdings [GNLN] $5.91 (+32.81%) Greenlane Holdings announced an exclusive contract for distributing drug detection test strips. Instil Bio [TIL] $64.31 (-23.91%) Instil Bio shares plummeted today following a new “Sell” rating from MarketsMOJO for high debt and a questionable financial structure. ITeos Therapeutics [ITOS] $12.10 (-27.54%) ITeos faces troubling news as three patients die during one of its cancer studies. Childrens Place Inc [PLCE] $12.21 (-15.91%) Children’s Place continues to dip as analysts place its valuation firmly in oversold territory. Security [An AI Stock Ready to Break Out]( While the big names dominate the headlines, this overlooked AI company is quietly revolutionizing public safety. With the global security robots market projected to hit $120 billion by 2030, this company is strategically positioned to capture massive gains. Their 2023 revenue surged by 128%, yet with a market cap of just $35 million, this stock remains hugely undervalued. [Get in early on this AI breakthrough and tap into a high-growth opportunity before Wall Street takes notice.]( That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback! Thanks for reading. I'll see you at the next open! Best Regards, — Adam G. Elite Trade Club [Click here]( to get our daily newsletter straight to your cell for free. P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. [Privacy Policy]( | [Advertiser Disclosure]( [tw]( [ig]( [yt]( [tk]( *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails. [Privacy Policy]( | [Terms of Service]( Update your email preferences or unsubscribe [here]( © 2024 Elite Trade Media LLC 1969 Alafaya Tr., Suite #247 Orlando, Florida 32828, United States of America [Terms of Service](